The search for madness: A metaphasical trip through the basal ganglia

Schizophrenia: The Final Frontier - A Festschrift for Robin M. Murray

Volumn , Issue , 2012, Pages 71-85

  Morrison, Paul D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920568863     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203808771     Document Type: Chapter

References (67)

1. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., et al. (1998). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. American Journal of Psychiatry, 155(6), 761-767.
2. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 97(14), 8104-8109.
3. Adermark, L., & Lovinger, D.M. (2009). Frequency-dependent inversion of net striatal output by endocannabinoid-dependent plasticity at different synaptic inputs. Journal of Neuroscience, 29(5), 1375-1380.
4. Akhondzadeh, S., Safarcherati, A., & Amini, H. (2005). Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial. Progress in Neuropsychopharmacology & Biological Psychiatry, 29(2), 253-259.
5. Akhondzadeh, S., Shasavand, E., Jamilian, H., Shabestari, O., & Kamalipour, A. (2000). Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. Journal of Clinical Pharmacology & Therapeutics, 25(2), 131-137.
6. Andersen, M.B., Fuxe, K., Werge, T., & Gerlach, J. (2002). The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behavioral Pharmacology, 13(8), 639-644.
7. Angrist, B., Sathananthan, G., Wilk, S., & Gershon, S. (1974). Amphetamine psychosis: Behavioral and biochemical aspects. Journal of Psychiatric Research, 11, 13-23.
8. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T.E. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal, 325(7374), 1212-1213.
9. Bailey, C.H., Giustetto, M., Huang, Y.Y., Hawkins, R.D., & Kandel, E.R. (2000). Is heterosynaptic modulation essential for stabilizing Hebbian plasticity and memory? Nature Reviews Neuroscience, 1(1), 11-20.
10. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3), 764-774.
11. Bosi, D.C., Hallak, J.E. C., Dursun, S.M., Deakin, J.F. W., & Zuardi, A.W. (2003). Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. Journal of Psychopharmacology, 17(Suppl.), A55.
12. Broderick, P., & Benjamin, A.B. (2004). Caffeine and psychiatric symptoms: A review. Journal of the Oklahoma State Medical Association, 97(12), 538-542.
13. Brunstein, M.G., Ghisolfi, E.S., Ramos, F.L., & Lara, D.R. (2005). A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry, 66(2), 213-219.
14. Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007). Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neuroscience, 30(5), 211-219.
15. Caykoylu, A., Ekinci, O., & Kuloglu, M. (2008). Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: A case report. Progress in Neuropsychopharmacology & Biological Psychiatry, 32(5), 1349-1350.
16. Centonze, D., Rossi, S., De Chiara, V., Prosperetti, C., Battista, N., Bernardi, G., et al. (2007). Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. European Journal of Neuroscience, 25(6), 1631-1640.
17. Chen, C.K., Lin, S.K., Sham, P.C., Ball, D., Loh, E.W., Hsiao, C.C., et al. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine, 33(8), 1407-1414.
18. Chevaleyre, V., & Castillo, P.E. (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: A novel role of endocannabinoids in regulating excitability. Neuron, 38(3), 461-472.
19. Chiang, Y.C., & Chen, J.C. (2007). The role of the cannabinoid type 1 receptor and downstream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensi-tized rats. Journal of Neurochemistry, 103(6), 2505-2517.
20. Corbille, A.G., Valjent, E., Marsicano, G., Ledent, C., Lutz, B., Herve, D., et al., (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. Journal of Neuroscience, 27(26), 6937-6947.
21. Dsouza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.T., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29(8), 1558-1572.
22. Dickerson, F.B., Stallings, C.R., Origoni, A.E., Sullens, A., Khushalani, S., Sandson, N., et al. (2009). A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research, 109(1-3), 66-69.
23. Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T.R., et al. (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry, 195(6), 488-491.
24. Dixon, A.K., Gubitz, A.K., Sirinathsinghji, D.J., Richardson, P.J., & Freeman, T.C. (1996). Tissue distribution of adenosine receptor mRNAs in the rat. British Journal of Pharmacology, 118(6), 1461-1468.
25. Dratcu, L., Grandison, A., McKay, G., Bamidele, A., & Vasudevan, V. (2007). Clozapine-resistant psychosis, smoking, and caffeine: Managing the neglected effects of substances that our patients consume every day. American Journal of Therapeutics, 14(3), 314-318.
26. Freiman, I., Anton, A., Monyer, H., Urbanski, M.J., & Szabo, B. (2006). Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. Journal of Physiology, 575(3), 789-806.
27. Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M., & Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 2(4), 358-363.
28. Hilario, M.R., Clouse, E., Yin, H.H., & Costa, R.M. (2007). Endocannabinoid signaling is critical for habit formation. Frontiers in Integrative Neuroscience, 1, 6.
29. Houk, J.C., Bastianen, C., Fansler, D., Fishbach, A., Fraser, D., Reber, P.J., et al. (2007). Action selection and refinement in subcortical loops through basal ganglia and cerebellum. Philosophical Transactions of the Royal Society London B Biological Science, 362(1485), 1573-1583.
30. Howes, O.D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophrenia Bulletin, 35(3), 549-562.
31. Huestis, M.A., Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T., et al. (2001). Blockade of effects of smoked marijuana by the CB1-selective can-nabinoid receptor antagonist SR141716. Archives of General Psychiatry, 58(4), 322328.
32. Hundert, E.M. (1989). Philosophy, psychiatry and neuroscience: Three approaches to the mind. Oxford, UK: Oxford University Press.
33. Javitt, D.C. (2007). Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. International Review of Neurobiology, 78, 69-108.
34. Kim, H.H., & Liao, J.K. (2008). Translational therapeutics of dipyridamole. Arteriosclerosis Thrombosis & Vascular Biology, 28(3), S39-42.
35. Kreitzer, A.C., & Malenka, R.C. (2005). Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. Journal of Neuroscience, 25(45), 10537-10545.
36. Kreitzer, A.C., & Malenka, R.C. (2007). Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature, 445(7128), 643-647.
37. Kreitzer, A.C., & Malenka, R.C. (2008). Striatal plasticity and basal ganglia circuit function. Neuron, 60(4), 543-554.
38. Lesscher, H.M., Hoogveld, E., Burbach, J.P., van Ree, J.M., & Gerrits, M.A. (2005). Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. European Neuropsychopharmacology, 15(1), 31-37.
39. Leweke, F.M., Koethe, D., Pahlisch, F., Schreiber, D., Gerth, C.W., Nolden, B.M., et al. (2009). Antipsychotic effects of cannabidiol (17th EPA Congress, Lisbon, Portugal, January 2009). European Psychiatry, 24(Suppl. 1), s207.
40. Lieberman, J.A., Kane, J.M., & Alvir, J. (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berlin), 91(4), 415-433.
41. Long, L.E., Malone, D.T., & Taylor, D.A. (2006). Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology, 31(4), 795-803.
42. Lucas, P.B., Pickar, D., Kelsoe, J., Rapaport, M., Pato, C., & Hommer, D. (1990). Effects of the acute administration of caffeine in patients with schizophrenia. Biological Psychiatry, 28(1), 35-40.
43. McKenna, P. (2007). Schizophrenia and related syndromes. London, UK: Routledge.
44. Moreira, F.A., & Guimaraes, F.S. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology, 512(2-3), 199-205.
45. Morrison, P.D., & Murray, R.M. (2009). From real-world events to psychosis: The emerging neuropharmacology of delusions. Schizophrenia Bulletin, 35(4), 668-674.
46. Morrison, P.D., Zois, V., McKeown, D.A., Lee, T.D., Holt, D.W., Powell, J.F., et al., (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 39(10), 1607-1616.
47. Murray, R.M., Morrison, P.D., Henquet, C., & Di Forti, M. (2007). Cannabis, the mind and society: The hash realities. Nature Reviews Neuroscience, 8(11), 885-895.
48. Nieuwenhuys, R., Voogd, J., & van Huijzen, C. (2008). The human central nervous system. Berlin, Germany: Springer-Verlag.
49. Pasupathy, A., & Miller, E.K. (2005). Different time courses of learning-related activity in the prefrontal cortex and striatum. Nature, 433(7028), 873-876.
50. Pennartz, C.M., Berke, J.D., Graybiel, A.M., Ito, R., Lansink, C.S., van der Meer, M., et al. (2009). Corticostriatal interactions during learning, memory processing, and decision making. Journal of Neuroscience, 29(41), 12831-12838.
51. Pertwee, R.G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabi-varin. British Journal of Pharmacology, 153(2), 199-215.
52. Redgrave, P., & Gurney, K. (2006). The short-latency dopamine signal: A role in discovering novel actions? Nature Reviews Neuroscience, 7(12), 967-975.
53. Redgrave, P., Prescott, T.J., & Gurney, K. (1999). The basal ganglia: A vertebrate solution to the selection problem? Neuroscience, 89(4), 1009-1023.
54. Rolls, E.T., & Treves, A. (1997). Neural networks and brain function. Oxford, UK: Oxford University Press.
55. Schmidt, A.P., Bohmer, A.E., Antunes, C., Schallenberger, C., Porciuncula, L.O., Elisabetsky, E., et al. (2009). Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: Role of A1 adenosine receptors. British Journal of Pharmacology, 156(1), 163-172.
56. Seger, C.A., & Cincotta, C.M. (2006). Dynamics of frontal, striatal, and hippocampal systems during rule learning. Cerebral Cortex, 16(11), 1546-1555.
57. Shen, W., Flajolet, M., Greengard, P., & Surmeier, D.J. (2008). Dichotomous dopaminergic control of striatal synaptic plasticity. Science, 321(5890), 848-851.
58. Shindou, T., Arbuthnott, G.W., & Wickens, J.R. (2008). Actions of adenosine A2A receptors on synaptic connections of spiny projection neurons in the neostriatal inhibitory network. Journal of Neurophysiology, 99(4), 1884-1889.
59. Sills, T.L., Azampanah, A., & Fletcher, P.J. (2001). The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology (Berlin), 156(2-3), 187-193.
60. Thiemann, G., Di Marzo, V., Molleman, A., & Hasenohrl, R.U. (2008). The CB(1) can-nabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology Biochemistry & Behaviour, 89(3), 384-391.
61. Thiemann, G., van der Stelt, M., Petrosino, S., Molleman, A., Di Marzo, V., & Hasenohrl, R.U. (2008). The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioural Brain Research, 187(2), 289-296.
62. Wickens, J.R. (2009). Synaptic plasticity in the basal ganglia. Behavioural Brain Research, 199(1), 119-128.
63. Yin, H.H., Mulcare, S.P., Hilario, M.R., Clouse, E., Holloway, T., Davis, M.I., et al. (2009). Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nature Neuroscience, 12(3), 333-341.
64. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology, 23(8), 979-983.
65. Zuardi, A.W., Rodrigues, J.A., & Cunha, J.M. (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berlin), 104(2), 260-264.
66. Zuardi, A.W., Shirakawa, I., Finkelfarb, E., & Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berlin), 76(3), 245-250.
67. Zuurman, L., Roy, C., Schoemaker, R.C., Amatsaleh, A., Guimaeres, L., Pinquier, J.L., et al. (2008). Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. Journal of Psychopharmacology, 24(3), 363-371.